Motley Bio

Based in California, US, Motley Bio operates as a biotechnology company that conducts research and develops medical therapies by preventing and curing diseases. In December 2024, Motley Bio raised venture funding from Atlas. Motley Bio specializes in leveraging multiomics technology to unlock the complexities of disease biology. Their core offerings encompass a comprehensive suite of multiomics solutions, including genomics, proteomics, and metabolomics, designed to facilitate a deeper understanding of disease mechanisms at a molecular level.

These tools aim to advance precision medicine by enabling clinicians and researchers to identify biomarkers for disease diagnosis and treatment efficacy. The company's services cater to a diverse client base, including pharmaceutical companies, academic institutions, and healthcare providers, primarily targeting markets in North America, Europe, and parts of Asia. Motley Bio generates revenue through a combination of direct service contracts and collaborative partnerships within the biomedical sector. Clients engage in transactions typically structured around project-based agreements or long-term partnerships, whereby services are offered on a fee-for-service model or through retainer agreements.

  Motley Bio is focused on developing new products utilizing its multiomics platforms, with several offerings slated for release in early 2025. The company plans to expand its operations into Europe and parts of Asia by mid-2025 to tap into growing markets for personalized medicine. Recent venture funding raised in December 2024 will support these initiatives, allowing for enhanced research capabilities and product development.